High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease

Journal of Magnetic Resonance Imaging

Volumn 35, Issue 1, 2012, Pages 48-55

  Lotfipour, Ashley K ^a   Wharton, Samuel ^a   Schwarz, Stefan T ^a   Gontu, V ^a   Schäfer, Andreas ^a   Peters, Andrew M ^a   Bowtell, Richard W ^a   Auer, Dorothee P ^a   Gowland, Penny A ^a   Bajaj, Nin P S ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

iron; Parkinson's disease; pars compacta; substantia nigra; susceptibility

Indexed keywords

IRON;

ADULT; AGED; ARTICLE; BRAIN LEVEL; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAGNETISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ADULT; AGED; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 83755220891     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22752     Document Type: Article

References (50)

1. Gutteridge JM,. Iron and oxygen radicals in brain. Ann Neurol 1992; 32: S16-S21.
2. Minati L, Grisoli M, Carella F, De Simone T, Bruzzone MG, Savoiardo M,. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol 2007; 28: 309-313.
3. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009; 47: 435-441.
4. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378-1384.
5. Gattellaro G, Minati L, Grisoli M, et al. White matter involvement in idiopathic parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 2009; 30: 1222-1226.
6. Chan LL, Rumpel H, Yap K, et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1383-1386. (Pubitemid 350221424)
7. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M,. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 2004; 75: 481-484. (Pubitemid 38338784)
8. Fearnley JM, Lees AJ,. Aging and Parkinson's diseases: substantia nigra regional selectivity. Brain 1991; 14 (Pt 5): 2283-2301.
9. Martin WR, Wieler M, Gee M,. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70 (Pt 2): 1411-1417. (Pubitemid 351521933)
10. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S,. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson' disease. J Neurol 2006; 253: 26-32. (Pubitemid 43157384)
11. Atasoy HT, Nuyan O, Tunc T, Yorubulut M, Unal AE, Inan LE,. T2-weighted MRI in Parkinson's disease; Substantia-nigra pars compacta hypointensity correlates with the clinical scores. Neurol India 2004; 52: 332-337. (Pubitemid 39430186)
12. Vymazal J, Righini A, Brooks RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211: 489-495. (Pubitemid 29206821)
13. Bartzokis G, Cummings JL, Markham CH, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999; 17: 213-222. (Pubitemid 29053180)
14. Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008; 28: 1061-1067.
15. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD,. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000; 123: 2423-2431.
16. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA,. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335-341. (Pubitemid 24274912)
17. Gelman N, Gorell JM, Barker PB, et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rate and relaxation to estimated iron content. Radiology 1999; 210: 759-767. (Pubitemid 29124039)
18. Michaeli S, Oz G, Sorce DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 2007; 22: 334-340. (Pubitemid 46569686)
19. Hutchinson M, Raff U,. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am J Neuroradiol 2000; 21: 697-701. (Pubitemid 30210433)
20. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006; 17: 1215-1218. (Pubitemid 44051416)
21. Duyn JH, van Gelderen P, Li TQ, de Zwart JA, Koretsky AP, Fukunaga M,. High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci U S A 2007; 104: 11796-11801. (Pubitemid 47175092)
22. Schafer A, Wharton S, Gowland P, Bowtell R,. Using magnetic field simulation to study susceptibility-related phase contrast in gradient echo MRI. Neuroimage 2009; 48: 126-137.
23. Marques JP, Bowtell R,. Application of a fourier-based method for rapid calculation of field inhomogeneity due to spatial variation of magnetic susceptibility. Concept Magn Reson B Magn Reson Eng 2005; 25B: 65-78 (Pubitemid 40776540)
24. Wharton S, Bowtell R,. Whole-brain susceptibility mapping at high field: a comparison of multiple- and single-orientation methods. Neuroimage 2010; 53: 515-525.
25. Schweser F, Deistung A, Lehr BW, Reichenbach JR,. Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism? Neuroimage 2011; 54: 2789-2807.
26. Haacke EM, Xu Y, Cheng YC, Reichenbach JR,. Susceptibility weighted imaging (SWI). Magn Reson Med 2004; 52: 612-618. (Pubitemid 39108975)
27. Shmueli K, van Gelderen P, Li TQ, et al. High resolution human brain susceptibility maps calculated from 7 T MRI phase data. In: Proceedings of the 16th Annual Meeting of ISMRM, Toronto, 2008.
28. de Rochefort L, Brown R, Prince MR, Wang Y,. Quantitative MR susceptibility mapping using piece-wise constant regularized inversion of the magnetic field. Magn Reson Med 2008; 60: 1003-1009.
29. Wharton S, Schafer A, Bowtell R,. Susceptibility mapping in the human brain using threshold-based k-space division. Magn Reson Med 2010; 63: 1292-1304.
30. de Rochefort L, Liu T,. A weighted gradient regularisation solution to the inverse problem from magnetic field to susceptibility maps (magnetic source MRI): validation and application to iron quantification in the human brain. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, Hawaii, 2009.
31. Liu T, Spincemaille P, de Rochefort L, Kressler B, Wang Y,. Calculation of susceptibility through multiple orientation sampling (COSMOS): a method for conditioning the inverse problem from measured magnetic field map to susceptibility source image in MRI. Magn Reson Med 2009; 61: 196-204.
32. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529-1534. (Pubitemid 20351344)
33. Foster ER, Black KJ, Antenor-Dorsey JA, Perlmutter JS, Hershey T,. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. Brain Cogn 2008; 67: 1-10. (Pubitemid 351685743)
34. Ellison D, Love S, Chimelli LM, Harding B, Lowe JS, Vinters HV,. Neuropathology: a reference text for CNS pathology, 2nd edition. New York: Mosby; 2003. p 515-517.
35. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P,. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res 2003; 5: 35-43.
36. Schenck JF, Zimmerman EA,. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004; 17: 433-445. (Pubitemid 39549421)
37. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1-25. (Pubitemid 40269946)
38. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114 (Pt 4): 1953-1975.
39. Griffiths PD, Dobson BR, Jones GR, Clarke DT,. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999; 122 (Pt 4): 667-673. (Pubitemid 29158775)
40. Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68: 1820-1825. (Pubitemid 46791395)
41. Riederer P, Sofic E, Rausch WD, et al. Transition-metals, ferritin, glutathione, and ascorbic-acid in Parkinsonian brains. J Neurochem 1989; 52: 515-520. (Pubitemid 19037617)
42. Bolzoni F, Giraudo S, Lopiano L, Bergamasco B, Fasano M, Crippa PR,. Magnetic investigations of human mesencephalic neuromelanin. Biochim Biophys Acta 2002; 1586: 210-218. (Pubitemid 34311836)
43. Fasano M, Bergamasco B, Lopiano L,. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 2006; 96: 909-916.
44. Double KL, Gerlach M, Youdim MB, Riederer P,. Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl 2000: 37-58. (Pubitemid 32037184)
45. Gerlach M, Double KL, Youdim MB, Riederer P,. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006: 133-142. (Pubitemid 44622190)
46. Wolozin B, Golts N,. Iron and Parkinson's disease. Neuroscientist 2002; 8: 22-32. (Pubitemid 34101815)
47. Vymazal J, Zak O, Bulte JW, Aisen P, Brooks RA,. T1 and T2 of ferritin solutions: effect of loading factor. Magn Reson Med 1996; 36: 61-65. (Pubitemid 26196532)
48. Brem F, Hirt AM, Winklhofer M, et al. Magnetic iron compounds in the human brain: a comparison of tumour and hippocampal tissue. J R Soc Interface 2006; 3: 833-841. (Pubitemid 44901313)
49. Damier P, Hirsch EC, Agid Y, Graybiel AM,. The substantia nigra of the human brain-I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry. Brain 1999; 122: 1421-1436. (Pubitemid 29374121)
50. Sasaki M, Shibata E, Tohyama K, et al. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. Neuroreport 2008; 19: 1649-1654.